Durable MRD-Negative Remission With Blinatumomab and Venetoclax in Heavily Pretreated Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
{{output}}
Introduction: Tyrosine kinase inhibitors (TKIs) are standard therapy for Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL); however, relapsed or refractory disease remains challenging due to resistance dri... ...